Introduction
Glomeruli, the filtering units of the kidney, are composed of several cell types including epithelial, mesangial and endothelial cells (1, 2) . Recent studies suggest that glomerular cells are intimately involved in regulating glomerular hemodynamics and actively participate in modulating responses to pathologic stimuli (1) (2) (3) (4) (5) (6) (7) (8) (9) . The availability of techniques to isolate and culture homogenous preparations of glomerular cells have advanced our knowledge of the functions and properties of intrinsic glomerular cells (1, 2) . Particular attention has focused on glomerular mesangial cells (MC) .' MC are specialized perivascular cells with diverse characteristics. In addition to their ability to synthesize glomerular basement membrane and me- 1 . Abbreviations used in this paper: DVF 12 medium, Dulbecco-Vogt modified Eagle's:Ham 12 medium; HFF, human foreskin fibroblasts; IL-1, interleukin 1; MC, mesangial cells; MCCM, mesangial cell conditioned medium; PAGE, polyacrylamide gel electrophoresis; PDGF, platelet-derived growth factor; PDS, plasma-derived serum.
sangial matrix components such as collagen and fibronectin, they possess receptors for a number of hormones and inflammatory mediators that may regulate their function in physiologic or pathologic states (4) (5) (6) (7) . MC exhibit smooth musclelike properties and contract in response to vasoactive hormones (4) (5) (6) (7) , synthesize potent inflammatory mediators such as oxygen-derived radicals (8) , cyclooxygenase and lipooxygenase products (5, 8) , and release a neutral proteinase capable of digesting glomerular basement membrane (9) . Of particular interest are the recent observations that rat glomerular MC produce erythropoietin (10) as well as a mitogen that closely resembles macrophage interleukin 1 (IL-1) (1 1). While exploring the mitogenic activity of rat mesangial cell conditioned medium (MCCM) on several target cells, we discovered that these cells release a protein indistinguishable immunologically and physiochemically from platelet-derived growth factor (PDGF). PDGF, a heat stable polypeptide, is the major mitogen in serum for a variety of cells of mesenchymal origin (12) (13) (14) (15) (16) . It is stored in the alpha-granules of platelets and is released into the serum during blood clotting. While platelets are the primary source of this growth factor activity in the serum, several studies have shown that nonplatelet cells are capable of producing and releasing a PDGF-like protein. PDGF or a closely related molecule is synthesized and released by transformed or malignant cells in culture (17) (18) (19) (20) . The demonstration that PDGF has extensive sequences homology with the putative transforming protein of simian sarcoma virus (15) , suggest that PDGF may be involved in the abnormal growth of malignant cells. Recent studies show that PDGF-like protein may also be secreted by nontransformed proliferative cells (21) (22) (23) (24) (25) . DiCorleto et al. have recently re- ported that cultured endothelial cells from several species produce several mitogens, one of which is biochemically and immunologically related to PDGF (21, 25) . This report describes the production by rat cultured MC ofa growth factor molecule that shares physiochemical and immunologic characteristics with PDGF. The potential implication of this finding is also discussed.
Methods
Materials. Human PDGF purified to homogeneity, partially purified human PDGF, and monospecific goat anti-human PDGF IgG were tested for purity and specificity and kindly provided by Dr. Russell Ross, University of Washington, Seattle, WA. PDGF preparations were purified from outdated human platelets through multiple column chromatography steps as previously described (26) . Pure PDGF was radioiodinated by the iodine monochloride method (27, 28) to a specific activity of 40 ,000 cpm/ng. The purity of the PDGF preparation was analyzed by SDS polyacrylamide gel electrophoresis (PAGE) on a 15% gel followed by autoradiography. The purity of the PDGF preparations used exceeds 90%. Labeled PDGF preparations are routinely tested for mitogenic as well as binding activities (26) (27) (28) . Antibody to purified human PDGF was prepared in a goat, and purified by Na2SO4 precipitation and chromatography on DEAE-Sephacel. Control IgG from a nonimmunized goat was prepared in the same manner. The anti-PDGF antibody has been shown to specifically block the binding and mitogenic activity of purified human PDGF but not the mitogenic effect of other growth factors such as fibroblast growth factor and epidermal growth factors to target cells (19 (2 mM) and L-glutamine (4 mM). Unless indicated otherwise, these cultures were maintained in medium containing 5% serum (Hy-Clone, Logan UT). Preparation of plasma-derived serum. Cell-free plasma-derived serum (PDS) was prepared from citrated whole blood ofhuman volunteers as previously described (23, 30) . Briefly, blood was collected in prechilled syringes containing sodium citrate, transferred to cold plastic centrifuge tubes and centrifuged to remove all blood cell elements at 30,000 g for 20 min. Plasma was recalcified by the addition ofCaCl2 to a final concentration of 20 mM and allowed to clot for 2 h at 37°C. Clotted material was removed by centrifugation at 400 g for 30 min at 4°C. Plasma-derived serum was filter sterilized and stored at -70°C.
Preparation ofcellfree conditioned media. MC were grown to confluence in 22 mm or 35 mm multiwell dishes (Costar) in 1 or 2 ml, respectively, of MC culture medium (RPMI + FCS). This medium was aspirated and cells washed three times with serum free RPMI containing the antibiotics and buffered with Hepes to pH 7.4 and incubated in the same medium for 24 h. This first medium collection was discarded to exclude any contamination with serum. Subsequent collections were made from cells reincubated with serum free RPMI for 48 or 72 h. Medium from wells is collected into conical centrifuge tubes, and centrifuged to remove cell debris at 5,000 rpm for 5 min, in a Sorvall centrifuge. The supernatant was stored at 0-4°C until assayed.
Radioreceptor assay for PDGF-like protein. The concentration of PDGF-like protein in MCCM was measured by a radioreceptor assay as previously described (21, 27, 28) . This assay measures the competitive activity of the test sample with 1251I-PDGF for binding to PDGF receptors on HFF. Unlike standard simultaneous competition assays the protocol of this assay involves preincubating the target cells with PDGF standard or test sample, aspirating the medium and adding binding medium containing '251-PDGF. The assay therefore depends on the ability of the bound receptor during the preincubation with purified PDGF or test substance to remain blocked during subsequent incubation with '25I-PDGF (28) . This sequential incubation protocol excludes detection ofspurious amounts ofPDGF secondary to binding of the label to binding components in the test sample, and for reasons discussed (19) helps increase the sensitivity of the assay. Subconfluent HFF were plated at a density of 1.5 X I04 cells/cm2 in 24 well plates in 1 ml medium containing 1% PDS. Cells were used 4-10 d after plating. Plates were placed on crushed ice and washed with 0.5 ml of ice-cold binding medium. This medium is Dulbecco-Vogt medium without bicarbonate containing 25 mM Hepes buffer pH 7.2 and 2 mg/ml BSA. Binding medium alone or binding medium containing varying aliquots of MCCM or standard concentrations ofpure PDGF was then added to the cells. In the experiments where the effects of anti-PDGF antibody was tested, MCCM or pure PDGF samples were preincubated in the presence or absence of antibody or identical amonts of control IgG in sterile siliconized microcentrifuge tubes for 1-h at 220C
with rotary shaking every 10 min. The concentration ofthe anti-PDGF IgG was adjusted such that the amount of the antibody relative to the amount of PDGF in all the samples remains constant. Aliquots from each preincubation condition were then transferred to the cells (HFF). Cells were then incubated for 2 h at 4VC with gentle shaking on an oscillating table. Medium was aspirated and cells washed three times with binding medium. 0.5 ml of binding medium containing 0.2 ng '25I-P[F was then added to each well and incubation continued for an additional 2 h at 4VC. At the end of this incubation, medium was aspirated and cells washed three times with 1 ml ice-cold PBS containing BSA at 1 mg/ml and 1 mM Ca2+. Bound radioactivity was determined by solubilizing the cells with 1% Triton X-100 containing BSA 1 mg/ml. PDGF-like protein was quantitated from standard curves obtained from wells containing 0.05, 0.1, and 0.2 ng unlabeled pure PDGF. Nonspecific binding was determined as the amount of 1251. PDGF bound in the presence of 100-fold excess of partially purified PDGF and averaged 5%. Data were expressed as nanograms PDGF equivalent/105 cells. In some experiments, PDGF-like protein was also expressed as units of competitor activity, where one unit is equivalent to 1% inhibition of 1251 binding. Competitor activity ofall samples and standards were determined in duplicate or triplicate wells. In one experiment, and to exclude a damaging effect of MCCM on the PDGF receptor, we also tested the effect ofacetic acid wash on the competitor activity of MCCM for the subsequent binding of '251-PDGF (31, 32) . Duplicate dishes of HFF were incubated at 4°C for 2 h with MCCM, crude PDGF, or binding medium as described earlier for the radioreceptor assay. One group of dishes representing each incubation condition was subsequently washed with binding medium while the other group was washed with binding medium followed by a 3-min incubation at 4°C with 0.2 M acetic acid in 150 mM NaCI with 1 mg/ml BSA, pH 3.12. All dishes were subsequently washed twice with binding medium and 251I-PDGF binding determined as described earlier. dine (0.5 pCi/ml) in a total volume of0.5 ml and cells reincubated for 4 h at 370C. The assay was terminated by aspiration ofthe medium and washing the cells twice with 5% TCA. Cells from individual wells were harvested by the addition of0.7 ml of0.25 NaOH and the radioactivity in 0.5-ml aliquots was determined by liquid scintillation counting.
To determine the ratio of mitogenic to competitor activity present in MCCM, pooled MCCM was concentrated 20-fold by ultrafiltration (Amicon Corp., Danvers, MA; YM-10 membrane) and centrifuged. Mitogenic and competitive activities were assayed as described earlier on serial dilutions of the concentrate of MCCM in the presence of standard concentrations of PDGF in both assays.
Biochemical characterization ofcompetitor activity in MCCM: Effect of trypsin. Serum free MCCM was collected as described earlier, concentrated 36 fold by ultrafiltration (YM-10 membrane) and centrifuged. A 1-ml aliquot of this concentrate was incubated with 300 pg of trypsin at 370C for 1 h. Soybean trypsin inhibitor (660 gg) was then added to neutralize trypsin. The same concentration of soybean trypsin inhibitor was added to another 1.0-ml aliquot as control. Aliquots were stored at 4VC, till assayed. PDGF-like competitive activity was assayed on serial dilutions of both aliquots.
Gel chromatography
Collected serum free MCCM was concentrated 20-fold and dialyzed against 50 mM ammonium acetate pH 7.5. 1.5 ml of this concentrate was applied to a column of Sephacryl S-200 (Pharmacia Fine Chemicals, Piscataway, NJ) equilibrated in 1.0 M acetic acid adjusted to pH 3.0 with concentrated NH4OH. Collected fractions were lyophilized, reconstituted in 5 mM acetic acid and monitored for mitogenic and competitor activity as described earlier. An aliquot of '25I-labeled pure PDGF was added to the MCCM before elution and fractions were tested for radioactivity in a gamma counter.
Ion exchange chromatography MCCM was concentrated as described earlier, and the concentrated solution dialyzed exhaustively against I mM NH4HCO3, pH 8.0 and adjusted to 0.1 M NH4HCO3 by the addition of NH4HCO3. This solution was applied to a 1.5 X 28 cm column of CM Sephadex G-50 equilibrated at room temperature with 0.1 M NH4HCO3, pH 8.0. After washing, a linear gradient of NH4HCO3 from 0.1 to 1.0 M was started.
Fractions were Iyophilized and resuspended in 5 mM acetic acid containing 2 mg/ml BSA and were assayed for PDGF competitor and total mitogen activity.
Results
In preliminary experiments, and using the radioreceptor assay, we found that preincubation of increasing concentrations of MCCM with HFF inhibit the subsequent binding of 1251-PDGF to the cells in a dose-dependent manner. In contrast to the effect of MCCM, control (nonconditioned serum-free RPMI), at various concentrations, had no effect on 1251-PDGF binding to the same fibroblast cultures. Table I shows the concentration of PDGF-like protein released into conditioned medium of confluent primary and first passage MC from four separate MC cell cultures. Since the molecule released by rat mesangial cells may not be identical to human PDGF, the concentration of this molecule was expressed as "ng PDGF equivalent" rather than PDGF. When expressed per cell number, the competitor activity released by MC does not decline with cell passage. We observed that MC creased from 91±11 to 421±3, 621±83, and 708±36. However, the mitogenic activity of MCCM, unlike the competitor activity, was only partially blocked by preincubating the conditioned medium with anti-PDGF antibody. Only 33-41% of the mitogenic activity of MCCM was blocked with anti-PDGF antibody in concentrations that totally abolished the mitogenic activity of equivalent concentrations of pure PDGF and the competitive activity of MCCM. Preincubation with control nonimmune IgG, on the other hand, had no significant effect on the mitogenic activity ofMCCM. Comparable counts in the presence of anti-PDGF IgG were 305+±16, 405+48, and 495±24, and 342±9, 581+17, and 629±47, in the presence of control IgG Fig. 4 b. These data suggest the presence of multiple mitogens in MCCM, one of which is recognized by the anti-PDGF antibody.
When equal aliquots from the same concentrated sample of MCCM were assayed for competitive and mitogenic activity, the concentration of PDGF-like activity in the mitogenic assay was 26.7±4.8 and in the competitor assay 2.20±0.1 1 ng PDGF eq/ml (mean±SD of triplicate aliquots), a ratio of 12:1. We also studied the effect of the proteolytic enzyme trypsin on the competitor activity of MCCM. Trypsin treatment of three aliquots of concentrated MCCM containing > 0.1 ng PDGF equivalent and providing > 50% competition resulted in a complete loss of the competitor activity, documenting the peptide nature of the molecule.
Sephacryl S-200 molecular sieving of a concentrate of MCCM under dissociating conditions (1% acetic acid, pH 3.0), revealed a broad peak of PDGF-like protein that contained both the competitor and the mitogenic activity, this peak coeluted with pure 125I human PDGF indicating a similar molecular weight (Fig. 5) . The appearance of all the mitogenic activity within this broad peak suggest that the molecular weight of the other mitogens falls within the same range, of the PDGFlike protein.
The gel chromatography step does not separate the PDGF from the non-PDGF mitogen. Since PDGF is a highly cationic protein, concentrated MCCM was subjected to cation exchange chromatography and collected fractions were analyzed for competitor and mitogenic activity. Using this ion exchange chiomatography, the mitogenic activity eluted into two peaks. The first and least cationic peak contained the bulk of the mitogen activity and measurable PDGF-like competitor activity while the second minor mitogen peak had a comparable amount of mitogenic and competitor activity (Fig. 6 ). The measurable competitor activity seen in the first mitogen peak is likely due to column overloading. It constitutes only a small fraction of the total mitogen activity present in the first peak hence, the inability of the antibody to have measurable effect on the total mitogen activity present in this peak. The presence of near equal amounts ofcompetitor and mitogen activities in the second peak and the fact that anti-PDGF IgG inhibits 70% of this mitogen activity (1.6±0.1 with IgG vs. 0.48+0.06 with In addition to its competitor activity, MCCM similar to PDGF possesses a potent mitogenic activity to HFF. Experiments utilizing anti-PDGF antibody, show that while this antibody completely abolishes the mitogenic activity of pure PDGF on HFF, it only partially inhibits the mitogenic activity of MCCM. The inability of the antibody to PDGF to remove all the mitogenic activity from MCCM is most likely due to the presence of multiple mitogens in the conditioned medium one of which is similar to PDGF and is recognized by anti-PDGF antibody. It is also possible, that the differential effect of anti-PDGF antibody on the mitogenic effect of pure human PDGF and MCCM reflect differences in the antigenic determinants between the human platelet PDGF and the rat mesangial PDGF-like molecule. This possibility is unlikely, however, in view of our finding that the anti-PDGF antibody employed, completely abolished the competitor activity of MCCM. The high ratio of mitogenic to competitive activities present in MCCM also suggests that MC secrete other mitogens besides PDGF. It should be emphasized that while the radioreceptor assay determines molecules that are able to bind to the PDGF receptor, the mitogen assay determines the combined effect of all mitogens present. The production of multiple mitogens by cultured diploid cells is not a unique feature of the MC. PDGF-like molecules account for only a small percentage of the mitogenic activity produced in serum-free medium conditioned by human vascular endothelial cells in culture (21, 25) .
Physiochemical characterization of the PDGF-like activity of the MCCM also revealed similarities with purified human PDGF. PDGF-like activity in MCCM similar to purified PDGF is sensitive to trypsin confirming the peptide nature of this molecule. Gel filtration chromatography on Sephacryl S-200 provide further evidence of the similarity of this molecule to PDGF. Both the PDGF-like competitor activity and the total mitogenic activity present in MCCM coeluted with pure labeled PDGF, indicating a similar molecular weight. While the gel chromatography step shows that the total mitogen activity elutes under a broad peak and does not separate the PDGF-like from the non-PDGF-like mitogen, the data with the ion exchange chromatography clearly shows the pres- (36) , and smooth muscle cells (37, 38) . Moreover, PDGF activates neutrophils and monocytes with subsequent release of potent inflammatory mediators such as superoxide anion and lysosmal enzymes (39, 40) . Both neutrophils and monocytes are prominent components of the glomerular hypercellularity observed in a number of immune inflammatory glomerular diseases observed in experimental animals and man (41, 42) . In vivo and in vitro studies in animals models of glomerular diseases have established a central role for these inflammatory cells in mediating the changes not only in renal hemodynamics and proteinuria, but also in glomerular cell proliferation (43 
